JP2000512652A5 - - Google Patents

Download PDF

Info

Publication number
JP2000512652A5
JP2000512652A5 JP1998502317A JP50231798A JP2000512652A5 JP 2000512652 A5 JP2000512652 A5 JP 2000512652A5 JP 1998502317 A JP1998502317 A JP 1998502317A JP 50231798 A JP50231798 A JP 50231798A JP 2000512652 A5 JP2000512652 A5 JP 2000512652A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1998502317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000512652A (ja
Filing date
Publication date
Priority claimed from DE19624668A external-priority patent/DE19624668A1/de
Application filed filed Critical
Publication of JP2000512652A publication Critical patent/JP2000512652A/ja
Publication of JP2000512652A5 publication Critical patent/JP2000512652A5/ja
Withdrawn legal-status Critical Current

Links

JP10502317A 1996-06-20 1997-06-20 腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび/またはピリジルアルキン酸アミド類の用途 Withdrawn JP2000512652A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19624668A DE19624668A1 (de) 1996-06-20 1996-06-20 Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
PCT/EP1997/003244 WO1997048397A1 (en) 1996-06-20 1997-06-20 Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624668.7 1997-06-20

Publications (2)

Publication Number Publication Date
JP2000512652A JP2000512652A (ja) 2000-09-26
JP2000512652A5 true JP2000512652A5 (cg-RX-API-DMAC10.html) 2005-02-10

Family

ID=7797502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10502317A Withdrawn JP2000512652A (ja) 1996-06-20 1997-06-20 腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび/またはピリジルアルキン酸アミド類の用途

Country Status (10)

Country Link
EP (1) EP0912176B1 (cg-RX-API-DMAC10.html)
JP (1) JP2000512652A (cg-RX-API-DMAC10.html)
AT (1) ATE224713T1 (cg-RX-API-DMAC10.html)
AU (1) AU3262497A (cg-RX-API-DMAC10.html)
DE (2) DE19624668A1 (cg-RX-API-DMAC10.html)
DK (1) DK0912176T3 (cg-RX-API-DMAC10.html)
ES (1) ES2181006T3 (cg-RX-API-DMAC10.html)
PT (1) PT912176E (cg-RX-API-DMAC10.html)
WO (1) WO1997048397A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA975443B (cg-RX-API-DMAC10.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
JPH10338658A (ja) * 1997-04-08 1998-12-22 Hoechst Marion Roussel Kk レチノイド作用調節剤
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
DE19756212A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756261A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
US6291459B1 (en) * 1998-08-12 2001-09-18 Smithkline Beecham Corporation Calcilytic compounds
EP1031564A1 (en) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
DE19908483A1 (de) * 1999-02-26 2000-10-05 Klinge Co Chem Pharm Fab Inhibitoren der zellulären Niacinamidmononucleotid-Bildung
WO2002013802A2 (en) 2000-08-11 2002-02-21 Wyeth Method of treating estrogen receptor positive carcinoma
ES2527688T3 (es) 2000-09-29 2015-01-28 Glaxo Group Limited Derivados de morfolin-acetamida para el tratamiento de enfermedades inflamatorias
EP1348434A1 (en) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
GB0207445D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2601508C (en) 2005-03-17 2012-01-03 Pfizer, Inc. Cyclopropanecarboxamide derivatives
PE20071159A1 (es) 2005-10-31 2007-11-30 Schering Corp Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
HUP0600809A3 (en) * 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
RU2529468C2 (ru) 2008-06-24 2014-09-27 Топотаргет А/С Производные 1, 2-дигидроциклобутендиона в качестве ингибиторов фосфорибозилтрансферазы никотинамида
AU2009286604B2 (en) 2008-08-29 2015-05-28 Onxeo Dk, Branch Of Onxeo S.A., France Novel urea and thiourea derivatives
JP2012533530A (ja) 2009-07-17 2012-12-27 トポターゲット・アクティーゼルスカブ ニコチンアミドホスホリボシルトランスフェラーゼ阻害剤による癌治療の副作用の重症度を低下させるためのニコチン酸またはその前駆体もしくはプロドラッグ投与の有効性を予測するための方法
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
MX347889B (es) 2010-09-03 2017-05-17 Forma Tm Llc * Compuestos y composiciones novedosos para la inhibición de nampt.
WO2012031196A1 (en) 2010-09-03 2012-03-08 Forma Therapeutics, Inc. 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer
US9676721B2 (en) 2010-09-03 2017-06-13 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
ES2622881T3 (es) * 2010-09-29 2017-07-07 Intervet International B.V. Compuestos de N-heteroarilo
CN103347860A (zh) 2010-11-15 2013-10-09 Abbvie公司 Nampt抑制剂
SG190819A1 (en) 2010-11-15 2013-07-31 Abbvie Inc Nampt and rock inhibitors
KR20140027366A (ko) 2011-05-04 2014-03-06 포르마 티엠, 엘엘씨. Nampt의 억제를 위한 신규 화합물 및 조성물
US9555039B2 (en) 2011-05-09 2017-01-31 Forma Tm, Llc. Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
UA114323C2 (uk) 2012-05-11 2017-05-25 Еббві Інк. Інгібітори nampt
CA2873075A1 (en) 2012-05-11 2013-07-14 Abbvie Inc. Nampt inhibitors
CN104271572A (zh) 2012-05-11 2015-01-07 艾伯维公司 用作nampt抑制剂的噻唑羧酰胺衍生物
EP2847181A1 (en) 2012-05-11 2015-03-18 AbbVie Inc. Pyridazine and pyridine derivatives as nampt inhibitors
EP2925750A1 (en) 2012-11-29 2015-10-07 Karyopharm Therapeutics, Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
AU2014285019C1 (en) 2013-07-03 2019-05-02 Karyopharm Therapeutics Inc. Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
WO2015042414A1 (en) 2013-09-20 2015-03-26 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
MX2018001979A (es) 2015-08-18 2019-04-25 Karyopharm Therapeutics Inc (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.
WO2017117447A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
EP3528850A4 (en) 2016-10-18 2020-06-24 Seattle Genetics, Inc. Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
EP3615081A1 (en) 2017-04-27 2020-03-04 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
WO2019149637A1 (en) 2018-01-31 2019-08-08 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
CN119775198A (zh) 2018-05-04 2025-04-08 治疗方案股份有限公司 靶向癌症干细胞的癌症治疗
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
KR20220110744A (ko) 2019-11-06 2022-08-09 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료
US20240376074A1 (en) 2021-05-13 2024-11-14 Remedy Plan, Inc. Nampt inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778796A (en) * 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP2832979B2 (ja) * 1988-02-15 1998-12-09 武田薬品工業株式会社 不飽和カルボン酸アミド誘導体
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
AU7652391A (en) * 1990-04-10 1991-10-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyridine esters
US5352684A (en) * 1990-04-10 1994-10-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridines as medicaments

Similar Documents

Publication Publication Date Title
JP2001504701A5 (cg-RX-API-DMAC10.html)
JP2000517343A5 (cg-RX-API-DMAC10.html)
JP2000501771A5 (cg-RX-API-DMAC10.html)
JP2000501599A5 (cg-RX-API-DMAC10.html)
JP2000501018A5 (cg-RX-API-DMAC10.html)
JP2000501324A5 (cg-RX-API-DMAC10.html)
JP2001502986A5 (cg-RX-API-DMAC10.html)
JP2000502472A5 (cg-RX-API-DMAC10.html)
JP2000501338A5 (cg-RX-API-DMAC10.html)
JP2000501825A5 (cg-RX-API-DMAC10.html)
JP2000500874A5 (cg-RX-API-DMAC10.html)
JP2000512652A5 (cg-RX-API-DMAC10.html)
JP2000502485A5 (cg-RX-API-DMAC10.html)
JP2000502425A5 (cg-RX-API-DMAC10.html)
JP2000502568A5 (cg-RX-API-DMAC10.html)
JP2000501774A5 (cg-RX-API-DMAC10.html)
JP2000500912A5 (cg-RX-API-DMAC10.html)
JP2000502570A5 (cg-RX-API-DMAC10.html)
JP2000514155A5 (cg-RX-API-DMAC10.html)
JP2000501744A5 (cg-RX-API-DMAC10.html)
JP2000511953A5 (cg-RX-API-DMAC10.html)
JP2000501229A5 (cg-RX-API-DMAC10.html)
JP2000500857A5 (cg-RX-API-DMAC10.html)
JP2000502316A5 (cg-RX-API-DMAC10.html)
JP2000502714A5 (cg-RX-API-DMAC10.html)